Squarepoint’s Amylyx Pharmaceuticals AMLX Stock Holding History

Squarepoint’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,800	Closed	-$63.5K	–	4516
2024 Q4	$63.5K	Buy	+16,800	New	+$79.1K	﹤0.01%	4802

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Squarepoint's AMLX Position: Q2 2026 in Review

Squarepoint sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 114,877 shares — an estimated $1.6M sold.

Squarepoint first reported a position in AMLX in Q1 2022 and held it in 15 quarters. The position peaked at $2.69M in Q1 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Squarepoint reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 114,877 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
Squarepoint first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 15 quarters.
Squarepoint's Amylyx Pharmaceuticals position peaked at $2.69M in Q1 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.